Finding New Drugs for Visceral Leishmaniasis
Author Information
Author(s): Osorio Yaneth, Travi Bruno L., Renslo Adam R., Peniche Alex G., Melby Peter C.
Primary Institution: Department of Veterans Affairs Medical Center, Research Service, South Texas Veterans Health Care System, San Antonio, Texas, United States of America
Hypothesis
New drugs are needed to treat visceral leishmaniasis due to the limitations of current therapies.
Conclusion
The ex vivo splenic explant model is effective for identifying new compounds that can combat Leishmania donovani in a relevant biological context.
Supporting Evidence
- The ex vivo model showed excellent discrimination between active and inactive compounds.
- 239 of 4,035 compounds were identified as screening actives based on their Z score.
- 84 compounds were classified as lead compounds based on their in vitro therapeutic index.
Takeaway
Scientists created a special test using hamster spleen cells to find new medicines for a disease caused by tiny parasites. They found 84 promising new compounds that could help treat this disease.
Methodology
The study used an ex vivo splenic explant culture system from hamsters infected with Leishmania donovani to screen 4,035 chemical compounds for anti-leishmanial activity.
Limitations
The study primarily focused on in vitro results, and further in vivo evaluation is needed to confirm the efficacy of the identified compounds.
Participant Demographics
Female inbred Chester Beatty hamsters (6–8 weeks-old) were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website